TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02514005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: - Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: - Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: * Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
Study: NCT00461305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRSP 3 mg/EE 20 µg (13 cycles)
Description: 1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRSP 3 mg/EE 30 µg (6 cycles)
Description: 1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Study: NCT02099305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Description: Depression education curriculum delivered by trained school health education teachers or other school personnel
Study: NCT02479776

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell injection
Description: Injection of autologous bone marrow derived stem cells
Study: NCT03131596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUB dilatation therapy
Description: A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
Study: NCT04055454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-LASV
Description: The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-LASV
Description: The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
Study: NCT04182061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AMTE protocol
Description: The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
Study: NCT02436070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted text messages
Description: Subjects received text messages specific to post ED asthma follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General text messages
Description: Subjects received text messages generalized to children with asthma
Study: NCT04367467

Intervention type: OTHER
Intervention: Kidney Function Test
Description: Cystatin-C measurement
Study: NCT03590054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
Study: NCT02064972

Intervention type: OTHER
Intervention: Patients undergoing allo-HSCT, who manifest GvHD.
Description: Changes in CEC counts in relation to GvHD ONSET
Study: NCT00162266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: IV, 10 mg/Kg, monthly, for the duration of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study: NCT03785951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein
Description: Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein
Description: Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Study: NCT04672447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
Study: NCT01288950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
Study: NCT03785951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein
Description: Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Study: NCT01907503

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Evaluation of the balance of force platform

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Evaluation of the balance of force platform
Study: NCT03785951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein with Leucine
Description: Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein with Leucine
Description: Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein with Leucine
Description: Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.
Study: NCT00554099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: 6 - 400 mg tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary advice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary advice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Advice
Description: Dietary advice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic for Diverticulitis
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic for Diverticulitis
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic for Diverticulitis
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Study: NCT01864447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)
Study: NCT04972084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerscope group
Description: Treatment of Class II malocclusions using Powerscope appliance
Study: NCT00480259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperproteic nutrition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hyperproteic nutrition
Study: NCT01754194

Intervention type: PROCEDURE
Intervention: Gastric Sleeve Resection
Description: Laparoscopic Gastric Sleeve Resection
Study: NCT00876954

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normothermia
Description: Warming without increase in core temperature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermia
Description: Core hyperthermia (39 °C) for 2,5 hours
Study: NCT01754194

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass
Study: NCT02122809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take orally
Study: NCT03356509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be performed on a stationary bicycle ergometer.
Study: NCT03924999

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined decongestive treatment (CDT) & Combined exercise
Description: Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression & Combined exercise
Description: Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
Study: NCT02042313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined paravertebral infusion and single shot of TAP block
Study: NCT02238015

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
Study: NCT02961049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etched
Description: Selective enamel etched with 35% phosphoric acid for 15 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etched
Description: Selective enamel etched with 35% phosphoric acid for 15 seconds.
Study: NCT01916850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study: NCT00707746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05204056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iced normal saline
Description: Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iced normal saline
Description: Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
Study: NCT02961049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wash and dry
Description: Wash and dry with absorbent paper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wash and dry
Description: Wash and dry with absorbent paper.
Study: NCT05204056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion
Description: Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
Study: NCT02392403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI532 cochlear implant
Study: NCT03758690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Electromagnetic (HIFEM) Field Device
Description: The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
Study: NCT03308045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pEYS606
Description: pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
Study: NCT00586443

Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab, everolimus, panitumumab
Description: Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15.
Study: NCT02603445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCL201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCL201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Study: NCT02675335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03218553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
Study: NCT03149003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
Study: NCT00967161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motion analysis
Description: Motion analysis (Gait/EMG during walking and functional tasks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Motion analysis (Gait/EMG during walking and functional tasks)
Study: NCT04363047

Intervention type: OTHER
Intervention: 40ml blood sample
Description: We'll be collecting cells, DNA and serum.

Intervention type: OTHER
Intervention: 40ml blood sample
Description: We'll be collecting cells, DNA and serum.
Study: NCT00281190

Intervention type: PROCEDURE
Intervention: Blood drawing
Description: blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
Study: NCT03060239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
Study: NCT03084029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 international units